References
Baou M, Kohlhaas SL, Butterworth M,
Vogler M, Dinsdale D, Walewska R, et al. (2010). Role of NOXA and
its ubiquitination in proteasome inhibitor-induced apoptosis in chronic
lymphocytic leukemia cells. Haematologica95 (9): 1510-1518.
Bard JAM, Goodall EA, Greene ER,
Jonsson E, Dong KC, Martin A (2018). Structure and Function of the 26S
Proteasome. Annual review of biochemistry 87: 697-724.
Bray F, Ferlay J, Soerjomataram I,
Siegel RL, Torre LA, Jemal A (2018). Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers
in 185 countries. CA: a cancer journal for clinicians68 (6): 394-424.
Cano-Gonzalez A, Mauro-Lizcano M,
Iglesias-Serret D, Gil J, Lopez-Rivas A (2018). Involvement of both
caspase-8 and Noxa-activated pathways in endoplasmic reticulum
stress-induced apoptosis in triple-negative breast tumor cells.Cell death & disease 9 (2): 134.
Ciechanover A (1994). The
ubiquitin-proteasome proteolytic pathway. Cell79 (1): 13-21.
Dejure FR, Eilers M (2017). MYC and
tumor metabolism: chicken and egg. The EMBO journal36 (23): 3409-3420.
Du Y, Song L, Zhang L, Ling H, Zhang
Y, Chen H, et al. (2017). The discovery of novel, potent
ERR-alpha inverse agonists for the treatment of triple negative breast
cancer. European journal of medicinal chemistry 136:457-467.
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C, Parkin DM (2010). Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. International journal of cancer127 (12): 2893-2917.
Fribley A, Zeng Q, Wang CY (2004).
Proteasome inhibitor PS-341 induces apoptosis through induction of
endoplasmic reticulum stress-reactive oxygen species in head and neck
squamous cell carcinoma cells. Molecular and cellular biology24 (22): 9695-9704.
Fribley AM, Evenchik B, Zeng Q, Park
BK, Guan JY, Zhang H, et al. (2006). Proteasome inhibitor PS-341
induces apoptosis in cisplatin-resistant squamous cell carcinoma cells
by induction of Noxa. The Journal of biological chemistry281 (42): 31440-31447.
Harris MA, Miles MA, Shekhar TM,
Cerra C, Georgy SR, Ryan SD, et al. (2020). The Proteasome
Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and
Abdominal Osteosarcoma Metastases in Mice. Cancers12 (5).
Hochstrasser M (1995). Ubiquitin,
proteasomes, and the regulation of intracellular protein degradation.Current opinion in cell biology 7 (2): 215-223.
Hu T, Zhang J, Sha B, Li M, Wang L,
Zhang Y, et al. (2019). Targeting the overexpressed USP7 inhibits
esophageal squamous cell carcinoma cell growth by inducing NOXA-mediated
apoptosis. Molecular carcinogenesis 58 (1):42-54.
Itoh A, Nonaka Y, Ogawa T, Nakamura
T, Nishi N (2019). Galectin-9 induces atypical ubiquitination leading to
cell death in PC-3 prostate cancer cells. Glycobiology29 (1): 22-35.
Jana NR (2012). Protein homeostasis
and aging: role of ubiquitin protein ligases. Neurochemistry
international 60 (5): 443-447.
Johnson DE (2015). The
ubiquitin-proteasome system: opportunities for therapeutic intervention
in solid tumors. Endocrine-related cancer22 (1): T1-17.
Kao C, Chao A, Tsai CL, Lin CY,
Chuang WC, Chen HW, et al. (2013). Phosphorylation of signal
transducer and activator of transcription 1 reduces bortezomib-mediated
apoptosis in cancer cells. Cell death & disease 4:e512.
Kapoor P, Ramakrishnan V, Rajkumar SV
(2012). Bortezomib combination therapy in multiple myeloma.Seminars in hematology 49 (3): 228-242.
Kelly KR, Espitia CM, Mahalingam D,
Oyajobi BO, Coffey M, Giles FJ, et al. (2012). Reovirus therapy
stimulates endoplasmic reticular stress, NOXA induction, and augments
bortezomib-mediated apoptosis in multiple myeloma. Oncogene31 (25): 3023-3038.
Knorr KL, Schneider PA, Meng XW, Dai
H, Smith BD, Hess AD, et al. (2015). MLN4924 induces Noxa
upregulation in acute myelogenous leukemia and synergizes with Bcl-2
inhibitors. Cell death and differentiation22 (12): 2133-2142.
Kupperman E, Lee EC, Cao Y, Bannerman
B, Fitzgerald M, Berger A, et al. (2010). Evaluation of the
proteasome inhibitor MLN9708 in preclinical models of human cancer.Cancer research 70 (5): 1970-1980.
Lankes K, Hassan Z, Doffo MJ,
Schneeweis C, Lier S, Ollinger R, et al. (2020). Targeting the
ubiquitin-proteasome system in a pancreatic cancer subtype with
hyperactive MYC. Molecular oncology 14 (12):3048-3064.
Liang H, Fan JH, Qiao YL (2017).
Epidemiology, etiology, and prevention of esophageal squamous cell
carcinoma in China. Cancer biology & medicine14 (1): 33-41.
Lordick F, Mariette C, Haustermans K,
Obermannova R, Arnold D, Committee EG (2016). Oesophageal cancer: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for
Medical Oncology 27 (suppl 5): v50-v57.
Manasanch EE, Orlowski RZ (2017).
Proteasome inhibitors in cancer therapy. Nature reviews. Clinical
oncology 14 (7): 417-433.
Mariette C, Piessen G, Triboulet JP
(2007). Therapeutic strategies in oesophageal carcinoma: role of surgery
and other modalities. The Lancet. Oncology8 (6): 545-553.
Mimnaugh EG, Xu W, Vos M, Yuan X,
Isaacs JS, Bisht KS, et al. (2004). Simultaneous inhibition of
hsp 90 and the proteasome promotes protein ubiquitination, causes
endoplasmic reticulum-derived cytosolic vacuolization, and enhances
antitumor activity. Molecular cancer therapeutics3 (5): 551-566.
Minchenko OH, Tsymbal DO, Minchenko
DO, Ratushna OO (2016). The role of the TNF receptors and apoptosis
inducing ligands in tumor growth. Ukrainian biochemical journal88 (5): 18-37.
Morsi RZ, Hage-Sleiman R, Kobeissy H,
Dbaibo G (2018). Noxa: Role in Cancer Pathogenesis and Treatment.Current cancer drug targets 18 (10): 914-928.
Mozos A, Roue G, Lopez-Guillermo A,
Jares P, Campo E, Colomer D, et al. (2011). The expression of the
endoplasmic reticulum stress sensor BiP/GRP78 predicts response to
chemotherapy and determines the efficacy of proteasome inhibitors in
diffuse large b-cell lymphoma. The American journal of pathology179 (5): 2601-2610.
Niewerth D, Jansen G, Assaraf YG,
Zweegman S, Kaspers GJ, Cloos J (2015). Molecular basis of resistance to
proteasome inhibitors in hematological malignancies. Drug
resistance updates : reviews and commentaries in antimicrobial and
anticancer chemotherapy 18: 18-35.
Nikiforov MA, Riblett M, Tang WH,
Gratchouck V, Zhuang D, Fernandez Y, et al. (2007). Tumor
cell-selective regulation of NOXA by c-MYC in response to proteasome
inhibition. Proceedings of the National Academy of Sciences of the
United States of America 104 (49): 19488-19493.
Nilsson JA, Cleveland JL (2003). Myc
pathways provoking cell suicide and cancer. Oncogene22 (56): 9007-9021.
Oakes SA, Papa FR (2015). The role of
endoplasmic reticulum stress in human pathology. Annual review of
pathology 10: 173-194.
Ooko E, Kadioglu O, Greten HJ,
Efferth T (2017). Pharmacogenomic Characterization and Isobologram
Analysis of the Combination of Ascorbic Acid and Curcumin-Two Main
Metabolites of Curcuma longa-in Cancer Cells. Frontiers in
pharmacology 8: 38.
Pelengaris S, Khan M, Evan G (2002).
c-MYC: more than just a matter of life and death. Nature reviews.
Cancer 2 (10): 764-776.
Piperdi B, Walsh WV, Bradley K, Zhou
Z, Bathini V, Hanrahan-Boshes M, et al. (2012). Phase-I/II study
of bortezomib in combination with carboplatin and bevacizumab as
first-line therapy in patients with advanced non-small-cell lung cancer.Journal of thoracic oncology : official publication of the
International Association for the Study of Lung Cancer7 (6): 1032-1040.
Ramirez PT, Landen CN, Jr., Coleman
RL, Milam MR, Levenback C, Johnston TA, et al. (2008). Phase I
trial of the proteasome inhibitor bortezomib in combination with
carboplatin in patients with platinum- and taxane-resistant ovarian
cancer. Gynecologic oncology 108 (1): 68-71.
Richardson P (2003). Clinical update:
proteasome inhibitors in hematologic malignancies. Cancer
treatment reviews 29 Suppl 1: 33-39.
Rosekrans SL, Heijmans J, Buller NV,
Westerlund J, Lee AS, Muncan V, et al. (2015). ER stress induces
epithelial differentiation in the mouse oesophagus. Gut64 (2): 195-202.
Sato A, Asano T, Isono M, Ito K,
Asano T (2014). Panobinostat synergizes with bortezomib to induce
endoplasmic reticulum stress and ubiquitinated protein accumulation in
renal cancer cells. BMC urology 14: 71.
Sato A, Asano T, Ito K, Asano T
(2012). Vorinostat and bortezomib synergistically cause ubiquitinated
protein accumulation in prostate cancer cells. The Journal of
urology 188 (6): 2410-2418.
Sato A, Asano T, Okubo K, Isono M,
Asano T (2017). Ritonavir and ixazomib kill bladder cancer cells by
causing ubiquitinated protein accumulation. Cancer science108 (6): 1194-1202.
Shirley M (2016). Ixazomib: First
Global Approval. Drugs 76 (3): 405-411.
Soldatenkov VA, Prasad S, Voloshin Y,
Dritschilo A (1998). Sodium butyrate induces apoptosis and accumulation
of ubiquitinated proteins in human breast carcinoma cells. Cell
death and differentiation 5 (4): 307-312.
Sosa Seda IM, Mott JL, Akazawa Y,
Barreyro FJ, Bronk SF, Kaufmann SH, et al. (2010). Noxa mediates
hepatic stellate cell apoptosis by proteasome inhibition.Hepatology research : the official journal of the Japan Society of
Hepatology 40 (7): 701-710.
Wirth M, Stojanovic N, Christian J,
Paul MC, Stauber RH, Schmid RM, et al. (2014). MYC and EGR1
synergize to trigger tumor cell death by controlling NOXA and BIM
transcription upon treatment with the proteasome inhibitor bortezomib.Nucleic acids research 42 (16): 10433-10447.
Yoshida GJ (2018). Emerging roles of
Myc in stem cell biology and novel tumor therapies. Journal of
experimental & clinical cancer research : CR 37 (1):173.
Yue D, Sun X (2019). Ixazomib
promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer
cells. Cancer biology & therapy 20 (3):284-294.
Zhang L, Liu P, Chen H, Li Q, Chen L,
Qi H, et al. (2016). Characterization of a selective inverse
agonist for estrogen related receptor alpha as a potential agent for
breast cancer. European journal of pharmacology 789:439-448.
Zhang L, Zhu Y, Cheng H, Zhang J, Zhu
Y, Chen H, et al. (2019). The Increased Expression of
Estrogen-Related Receptor alpha Correlates with Wnt5a and Poor Prognosis
in Patients with Glioma. Molecular cancer therapeutics18 (1): 173-184.
Zhao J, He YT, Zheng RS, Zhang SW,
Chen WQ (2012). Analysis of esophageal cancer time trends in China,
1989- 2008. Asian Pacific journal of cancer prevention : APJCP13 (9): 4613-4617.
Zhao Y, Foster NR, Meyers JP, Thomas
SP, Northfelt DW, Rowland KM, Jr., et al. (2015). A phase I/II
study of bortezomib in combination with paclitaxel, carboplatin, and
concurrent thoracic radiation therapy for non-small-cell lung cancer:
North Central Cancer Treatment Group (NCCTG)-N0321. Journal of
thoracic oncology : official publication of the International
Association for the Study of Lung Cancer 10 (1):172-180.